| « Previous month | Next month » |
In-Pharmatechnologist.com would like to wish all our readers a happy holiday
The US FDA is seeking information to help it protect celiac disease patients from pharma ingredients derived from wheat, barley, or rye.
Pall will buy US instrument maker ForteBio next year in a continuation of efforts to build its biomanufacturing technology offering.
Amgen has partnered with non-branded drugmaker Watson to develop biosimilar cancer drugs in a deal that goes some way towards protecting its own portfolio from generic competition.
Electroporation is the wave of the future for transdermal drug delivery, according to Parexel’s Ravi Harapanhalli.
It’s been a busy year for API (active pharmaceutical ingredient) manufacturers with new facilities, cost pressures and regulatory developments all hitting the headlines. And it seems recent developments in HPAPIs (high potency APIs) have caused a stir with news of the industry taking up the top 4 places of our end-of-year run-down. Here are the most read API stories from in-PharmaTechnologist in 2011…
Ranbaxy has signed a consent decree with the US FDA and set aside $500m for penalty payments to settle its longstanding dispute.
Eli Lilly is collaborating with Arecor to develop stable aqueous or higher concentration formulations of protein and peptide drugs.
Intracellular drug delivery testing could become quicker thanks to probes that "light up" when a medicine is delivered to a tumour.
DSM Biologics will work with the Australian Institute for Bioengineering and Nanotechnology (AIBN) on the commercialisation of development-stage biologics projects.
China will keep its position as a leading API and intermediates supplier thanks to recovering global demand and the growth of the generic sector say market analysts.
Eli Lilly has expanded its drug delivery partnership with Starpharma to include further in vivo studies and clinical testing.
Counterfeit anti-malarials containing the Viagra API were probably manufactured in Southeast Asia, researchers found.
BASF has raised its prices for three ethanolamines (EOA), key intermediates in the production of a wide range of active pharmaceutical ingredients (API).
Drug-loaded lollipops are the ideal dosage form to boost compliance in children with oral thrush, Indian researchers found.
in-PharmaTechnologist presents its weekly round-up of the latest appointments within the pharmaceutical industry, including news from Vertex, Pfizer and Prolong.
Manufacturers of certain critical drugs must report production interruptions to the FDA under a new interim final rule.
GE Healthcare wont say if its new turnkey biologics plant development service will offer Governments in emerging nations discounted rates.
Seppic has seen a boom in demand for its new natural origin coating agents for pharmaceuticals, which can speed up production time by 50 per cent at lab stage.
Researchers have developed a Trojan-horse-style delivery system that transports steroids to the retina for the treatment of age-related macular degeneration and retinitis pigmentosa.
A treaty on medicine quality is needed to fix the major public health problem of substandard drugs, according to academics.
AMPAC posted a fourth quarter loss as process improvement difficulties offset rising demand for CNS and oncology ingredients.
UK-headquartered Archimedes Pharma has licensed its Targit drug delivery tech to Sweden’s Pharmalink AB for its candidate renal failure treatment, Nefecon.
GE Healthcare and M+W Group aim to capture a share of the rapidly expanding global biologics market with a new plant and manufacturing tech partnership.
The EMA has recommended recalling a batch of Gilead’s Vistide manufactured by Ben Venue over particle contamination concerns.
ADC Biotechnology (ADC Bio) has secured a development grant for a new antibody drug conjugate (ADC) manufacturing technology that, it says, can make drug production cheaper.
The FDA and the EMA will begin sharing facility inspection data in their respective territories from January to make better use of resources and reduce drugmakers’ inspection burdens.
Hospira says Chairman Christopher Begley’s impending retirement is unrelated to quality problems at manufacturing plant or recent investor criticism.
Scientists believe they have developed one-stop gene therapy that could almost eradicate haemophilia.
Chemicals firm Vertellus Specialties has begun manufacturing operations at a new facility in China, citing growth of the country’s cyanopyridines market as the key driver for the investment.
in-PharmaTechnologist presents its round-up of the latest drug delivery developments, including multi-component particles, metering valve technology and crystalline salts.
UK drug maker AstraZeneca has bought Chinese non-branded drugmaker Guangdong BeiKang Pharma.
Outsourcing-Pharma presents its weekly round-up of the latest movers and shakers in the pharmaceutical industry, including news from Inviragen, Auxilium, and Icon Biosciences.
Drug delivery developers need more focus on the shape of the carrier, rather than the size and surface chemistry, according to a new study.
Mettler Toledo says its new dissolved oxygen (DO) measuring optical sensors can speed up the API production process and reduce maintenance costs.
Netherlands-based IMCD has bought Italian fine chemicals supplier Organotec Srl to expand its pharma actives across Europe.
US drug industry group PhRMA has backed FDA plans to discuss fees for biosimilars with pharmaceutical manufacturers.
US drugmaker Merck & Co has chosen Beijing, China as the site of its Asia R&D headquarters.
An injectable gel that releases drugs when triggered by an AA battery powered electric field could replace implants, say researchers.
Bosch Packaging Technology says melt extrusion is the answer to drug manufacturers’ active pharmaceutical ingredient (API) solubility questions.
Stevanato Group has pulled forward the expansion of its EZ-Fill facility in Italy by one year in a bid to dominate a bigger portion of the “rapidly expanding” ready-to-fill vials market.
in-PharmaTechnologist presents its weekly round-up of the latest changes within the pharmaceutical job sector, including news from Takeda, Immune Design, and Pharmacyclics.
US developer Ampio Pharmaceuticals says new orally disintegrating tablet (ODT) tech will boost market acceptance of its premature ejaculation rug.
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
Legal battles, patent acquisitions and R&D dominate in-pharmatechnologist.com’s round up of developments in drug delivery this week with news from MonoSol, Acacia and a US University team working on GSK’s Relenza.
The Ethiopian national quality control laboratory has gained ISO accreditation to improve access to safe medicines.
Actavis has bought Netherlands-based PharmaPack to cut its tablet packaging lead times and freight costs.
The US FDA has published draft guidance to help companies submit marketing applications for API-excipient co-crystals.
Biologics Modular is leasing its mobile production facilities to help clients make FDA regulated drugs without fixed plants.
Large volume production is a must for the cell therapy sector according to ATMI, which claims the latest addition to its single-use bioreactor range can help manufacturers overcome the GMP hurdles that hinder commercial scale-up.
India-based Vivimed Labs is buying Uquifa for £35m ($55m) to add API capabilities in Europe and Latin America.
in-PharmaTechnologist presents its round-up of the latest career moves within the world of pharmaceuticals, including news from AstraZeneca, Apricus, and BioTime.
The drug industry's need to improve product quality while reducing production costs is driving global demand for testing technologies according to Sepha.
Ranbaxy has introduced generic Lipitor in the US after partnering with Teva and gaining FDA approval for manufacture at its US plant.
| « Previous month | Next month » |